| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
EAI-001 targets mutant epidermal growth factor receptor (EGFR), specifically the L858R, T790M, and C797S mutations. It is an allosteric inhibitor, meaning it binds to a site other than the ATP-binding pocket. This non-ATP competitive mechanism allows it to overcome resistance caused by ATP-binding site mutations.
|
|---|---|
| ln Vitro |
At 50 μM, EAI001 binds to EGFR T790M/C797S/V948R, which is situated far inside the protein and faces the C-helix and ATP binding site. Because of its hydrophobic interactions with the amino acids Ile759, Leu747, Leu788, Leu777, and Met766, EAI001 has inhibitory effect [1].
In vitro, EAI-001 is a potent inhibitor of mutant EGFR, with an IC50 of 24 nM against EGFRL858R/T790M. It is a non-ATP competitive inhibitor. |
| ln Vivo |
In vivo, EAI-001 has potential for cancer research, particularly in cancers driven by these EGFR mutations.
|
| Enzyme Assay |
In vitro non-cell-based assays for EAI-001 involve measuring its inhibition of EGFR kinase activity. The kinase is incubated with a substrate and ATP in the presence of varying concentrations of the compound, and the IC50 is determined.
|
| Cell Assay |
In vitro cell-based assays for EAI-001 are performed in cancer cell lines harboring the relevant EGFR mutations. Cells are treated with the compound, and cell proliferation, EGFR phosphorylation, and downstream signaling are measured.
|
| Animal Protocol |
In vivo animal experiments with EAI-001 could be conducted in mouse xenograft models of EGFR-mutant cancers to evaluate its anti-tumor efficacy.
|
| ADME/Pharmacokinetics |
EAI-001 has a molecular weight of 349.41 g/mol and the formula C19H15N3O2S. It is a solid powder with a purity of ≥98%.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for EAI-001 are not detailed in the available literature.
|
| References |
|
| Additional Infomation |
EAI-001 is a first-in-class non-ATP competitive allosteric inhibitor of mutant EGFR. It is being studied for its potential to overcome drug resistance in EGFR-mutant cancers. It is intended for research use.
|
| Molecular Formula |
C19H15N3O2S
|
|---|---|
| Molecular Weight |
349.406302690506
|
| Exact Mass |
349.088
|
| CAS # |
892772-75-7
|
| PubChem CID |
45370166
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
509
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1N(C(C(NC2SC=CN=2)=O)C2C=CC=CC=2)CC2C1=CC=CC=2
|
| InChi Key |
PWRVRDCBFYLYFU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H15N3O2S/c23-17(21-19-20-10-11-25-19)16(13-6-2-1-3-7-13)22-12-14-8-4-5-9-15(14)18(22)24/h1-11,16H,12H2,(H,20,21,23)
|
| Chemical Name |
2-(3-oxo-1H-isoindol-2-yl)-2-phenyl-N-(1,3-thiazol-2-yl)acetamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~286.20 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8620 mL | 14.3098 mL | 28.6197 mL | |
| 5 mM | 0.5724 mL | 2.8620 mL | 5.7239 mL | |
| 10 mM | 0.2862 mL | 1.4310 mL | 2.8620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
